RNXT RenovoRx Forecast, Technical & Fundamental Analysis
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment... Show more
RNXT is expected to report earnings to fall 22.22% to -7 cents per share on November 16
Q3'26
Est.
$-0.07
Q1'26
Missed
by $0.01
Q4'25
Est.
$-0.08
Q3'25
Est.
$-0.08
Q2'25
Beat
by $0.01
The last earnings report on May 14 showed earnings per share of -9 cents, missing the estimate of -7 cents. With 670.44K shares outstanding, the current market capitalization sits at 63.18M.
A.I.dvisor tells us that RNXT and RXRX have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RNXT and RXRX's prices will move in lockstep.
RNXT in upward trend: 10-day moving average crossed above 50-day moving average on August 03, 2026
The 10-day moving average for RNXT crossed bullishly above the 50-day moving average on August 03, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on July 27, 2026. You may want to consider a long position or call options on RNXT as a result. In of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for RNXT just turned positive on July 27, 2026. Looking at past instances where RNXT's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .
RNXT moved above its 50-day moving average on July 30, 2026 date and that indicates a change from a downward trend to an upward trend.
The 50-day moving average for RNXT moved above the 200-day moving average on August 13, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where RNXT advanced for three days, in of 231 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 100 cases where RNXT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RNXT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
RNXT broke above its upper Bollinger Band on August 14, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. RNXT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.037) is normal, around the industry mean (20.042). P/E Ratio (0.000) is within average values for comparable stocks, (24.309). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.844). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (28.090) is also within normal values, averaging (438.430).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RNXT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
